Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Martin Lázaro Quintela"'
Autor:
Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, Mehmet Artac, Martín Lázaro Quintela, Jong-Seok Lee, Maen Hussein, Miklos Pless, Luis Paz-Ares, Lance Leopold, Jeannie Daniel, Mihaela Munteanu, Ayman Samkari, Lu Xu, Charles Butts
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-11 (2024)
Abstract Background Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other immunotherapies may enhance tumor cell killing and clinical outcomes. Epaca
Externí odkaz:
https://doaj.org/article/778d9a0bf7f040a3adf76b4a236aef6f
Autor:
Martin Lázaro Quintela, F. Estevinho, N. Núñez, Virginia Calvo, R. Pinheiro, A. Figueiredo, Fernando Barata, A. Vaz, C. Benito, P. Fidalgo, S. Azevedo, A. Mendes, D. Corbacho, António Araújo, Sergio Vazquez-Estevez, B. Balea, M. Provencio, H. Magalhães
Publikováno v:
Journal of Thoracic Oncology. 16:S1053-S1054
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::183633add8a97a2d05bde8ad326a168e
https://doi.org/10.1016/j.jtho.2021.08.409
https://doi.org/10.1016/j.jtho.2021.08.409
Autor:
Rocio Vilchez Simo, Maria Carmen Areses Manrique, María Rosario García Campelo, Cristina Azpitarte Raposeiras, Jose Muñoz Iglesias, Joaquín Martínez, Urbano Anido Herranz, F.J. Afonso, Natalia Fernández Núñez, David Arias Ron, Begoña Campos Balea, Martin Lázaro Quintela, Juan Ruiz Bañobre, Jorge García González, Margarita Amenedo Gancedo, Lucía Santomé Couto, José Luis Fírvida Pérez, Joaquin Casal Rubio, Jesús García Mata, Guillermo Alonso-Jaudenes Curbera, Iria Carou Frieiro
Publikováno v:
Journal of geriatric oncology. 12(3)
Background Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line of treatment. Older patients are often not represented in clinical trials and dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8f0359c9eb9f002de01c36c87004c8
https://pubmed.ncbi.nlm.nih.gov/33357975
https://pubmed.ncbi.nlm.nih.gov/33357975
Autor:
Natalia Fernández Núñez, Martin Lázaro Quintela, Iria Carou Frieiro, Joaquin Mosquera Martinez, Margarita Amenedo Gancedo, Joaquin Casal Rubio, Jose Muñoz Iglesias, Alexandra Sabela Cortegoso mosquera, Rocio Vilchez Simo, Urbano Anido Herranz, Jesús García Mata, Lucía Santomé Couto, Begoña Campos Balea, Mª Carmen Areses Manrique, Jorge García González, Mª Rosario García Campelo, Guillermo Alonso-Jaudenes Curbera, José Luis Fírvida Pérez, Cristina Azpitarte Raposeiras, F.J. Afonso
Publikováno v:
Translational Lung Cancer Research. 7:404-415
Background Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data of real life is lacking. This is an observational study that represents the real world experience with nivol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc7bb30d30b4aba37c3cf312d55b53a
https://doi.org/10.21037/tlcr.2018.04.03
https://doi.org/10.21037/tlcr.2018.04.03
Autor:
Urbano Anido Herranz, Sergio Vázquez Estévez, Martin Lázaro Quintela, Lucía Santomé Couto, Ovidio Fernandez Calvo, Sonia Maciá Escalante, Luis Leon Mateos, F.J. Afonso
Publikováno v:
Critical Reviews in Oncology/Hematology. 107:119-127
Prostate cancer is the most frequent cancer amongst men. Until recently, only two therapeutic options, initial androgen-deprivation therapy in patients without castration-resistant prostate cancer, with addition of docetaxel when the disease becomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9c9fac9211c881d6d83748f46e0096
https://doi.org/10.1016/j.critrevonc.2016.08.007
https://doi.org/10.1016/j.critrevonc.2016.08.007
Autor:
Carlos Camps, Ilse Lugo, Alvaro Pinto, Enrique Gallardo Diaz, Cristina Anton, Fernando Caballero, Miguel Angel Climent Duran, Ignacio Duran, V. Guillem, Irene Santamaría Rodríguez, Francisco J Campos, Aranzazu Gonzalez del Alba, María José Méndez Vidal, Álvaro Rogado, Diana Monge, Javier Puente, Martin Lázaro Quintela
Publikováno v:
Journal of Clinical Oncology. 38:220-220
220 Background: The ECO Foundation (Excellence and Quality in Oncology) proposes to establish a set of healthcare quality measures (including indicators and standards) for the diagnosis, treatment and follow-up of renal cancer in Spain which all heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ace4699f4469271e0ed8d88dcd79ab46
https://doi.org/10.1200/jco.2020.38.29_suppl.220
https://doi.org/10.1200/jco.2020.38.29_suppl.220
Autor:
Pablo Maroto, Javier Cassinello, Martin Lázaro Quintela, Jose Angel Arranz Arija, Emilio Esteban, Ignacio Duran, Alfredo Sanchez-Hernandez, Daniel Castellano, María José Juan Fita, Miguel Angel Climent Duran, Javier Puente, Teresa Alonso Gordoa, María José Méndez Vidal, Albert Font, Begoña Mellado, Aranzazu Gonzalez del Alba, Carmen Santander, M Isabel Sáez, Begoña P. Valderrama
Publikováno v:
Journal of Clinical Oncology. 38:95-95
95 Background: Abiraterone acetate (AA) improves OS and rPFS in first line mCRPC patients (pts). After AA progression D is commonly used as standard second line therapy. However, the value of maintaining AA in combination with D despite progression h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e25799e52aa596b9a4518b357ef2e1c
https://doi.org/10.1200/jco.2020.38.6_suppl.95
https://doi.org/10.1200/jco.2020.38.6_suppl.95
Autor:
Cristina Azpitarte Raposeiras, Noemi De Dios Alvarez, Jorge Garcia, Vanesa Varela Pose, Martin Lázaro Quintela, Victor Cebey, F.J. Afonso, Manuel Constenla, Maria Carmen Areses Manrique, Sara Agraso Busto, Margarita Amenedo, Natalia Fernández Núñez, J. L. Fírvida, Begoña Campos Balea, Juan Ruiz Bañobre, Nazaret Quiroga Veiga
Publikováno v:
Journal of Clinical Oncology. 37:e20636-e20636
e20636 Background: First or second line crizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with NSCLC ALK positive and it was the first approved ALK inhibitor. However, there are limited data describing the use of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::931f32177dca505fc3aa9a66449d847c
https://doi.org/10.1200/jco.2019.37.15_suppl.e20636
https://doi.org/10.1200/jco.2019.37.15_suppl.e20636
Autor:
Natalia Fernández Núñez, Lucía Santomé, G. Huidobro, Cristina Azpitarte, Noemi De Dios Alvarez, Martin Lázaro Quintela, Jorge Garcia, J. L. Fírvida, Joaquin Casal Rubio, Begoña Campos Balea, F.J. Afonso, Maria Carmen Areses Manrique, Diego Pereiro Corbacho, Sara Agraso Busto, Vanesa Varela
Publikováno v:
Journal of Clinical Oncology. 37:e20654-e20654
e20654 Background: Treatment with tyrosine kinasa inhibitors has been a revolution for the patients with non-small cell lung cancer and EGFR positive mutation, especially in patients with exon 19 deletions. Afatinib seems one of the best options of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d8e2328756564cc45c2195487fb15a9
https://doi.org/10.1200/jco.2019.37.15_suppl.e20654
https://doi.org/10.1200/jco.2019.37.15_suppl.e20654
Autor:
Isaura Fernández Pérez, Diana Valverde, Concepción Fiaño Valverde, Jenifer Brea Iglesias, María José Villanueva Silva, Martín Lázaro Quintela, Bárbara Meléndez
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract Due to their rarity and heterogeneity and despite the introduction of molecular features in the current WHO classification, clinical criteria such as those from the European Organization for Research and Treatment of Cancer (EORTC) and the R
Externí odkaz:
https://doaj.org/article/46adbcd81f8f43abb2a49a1ce1f44dca